BDKRB1 as a Radioligand Therapy Target
BDKRB1, bradykinin receptor B1, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, BDKRB1 staining is highest in head and neck cancer (100% of samples positive), thyroid cancer (100% of samples positive) and neuroendocrine tumors (100% of samples positive). Evidence on whether BDKRB1 internalizes is mixed. Clinical status: Clinical-stage (up to phase 2, any modality).
Is BDKRB1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in head and neck cancer, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: Clinical-stage (up to phase 2, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
BDKRB1 expression in cancer
Protein expression of BDKRB1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Head and Neck Cancer | 1.00 | High | 100% |
| Thyroid Cancer | 1.00 | High | 100% |
| Neuroendocrine Tumors | 1.00 | High | 100% |
| Colorectal Cancer | 0.97 | High | 100% |
| Prostate Cancer | 0.97 | High | 100% |
| Breast Cancer | 0.94 | High | 100% |
| Testicular Cancer | 0.89 | High | 100% |
| Ovarian Cancer | 0.81 | High | 100% |
| Liver Cancer | 0.78 | High | 100% |
| Cervical Cancer | 0.76 | High | 100% |
| Lung Cancer | 0.76 | High | 100% |
| Endometrial Cancer | 0.76 | High | 100% |
| Melanoma | 0.71 | High | 100% |
| Pancreatic Cancer | 0.69 | High | 100% |
| Bladder Cancer | 0.67 | High | 100% |
| Lymphoma | 0.64 | High | 82% |
| Skin Cancer | 0.63 | High | 100% |
| Kidney Cancer | 0.61 | High | 100% |
| Gastric Cancer | 0.56 | High | 100% |
| Glioma | 0.46 | Medium | 82% |
Is BDKRB1 internalized?
Uncertain. Insufficient literature found.
BDKRB1 clinical trials
Clinical-stage (up to phase 2, any modality). Nuclens hasn't indexed trials for BDKRB1 yet. Search ClinicalTrials.gov for BDKRB1 trials.
BDKRB1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See BDKRB1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
BDKRB1 gene essentiality (DepMap)
CRISPR knockout effect across 1248 cancer cell lines: 0.14 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related head and neck cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · ITGAV · SSTR2 · B7-H3 (CD276) · STEAP2 · Mesothelin (MSLN)
See all radioligand therapy targets in head and neck cancer.
See how BDKRB1 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.